Comparison of efficacy of erythemal dose vs. suberythemal dose of excimer laser treatment in vitiligo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004342

Enrollment

Registered

2019-10-17

Start date

2018-04-18

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : The 308-nm EL treatment was conducted twice weekly on both sides for 3 months (EXL-440, Jetema, Seoul, Korea). Initial irradiation dose was 50 mJ/cm2 and 100 mJ/cm2 on the face, and 1

ointment (LEO Pharma Inc, Ballerup, Denmark) was applied twice daily in both groups for study period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients aged 18 years or older with stable vitiligo that was symmetrically distributed over their face and neck were recruited from our clinics The stable vitiligo was defined as the absence of new lesions and no increase in the size of existing lesions for 6 months prior to the enrollment.

Exclusion criteria

Exclusion criteria: The exclusion criteria included the patients taking systemic corticosteroids or immunosuppressants for last 4 weeks; having chemotherapy or immunotherapy for last 4 weeks; having phototherapy including EL for last 4 weeks.

Design outcomes

Primary

Measure	Time frame
The primary outcome was degree of repigmentation (%) from baseline in each side	—

Secondary

Measure	Time frame
The degree of perilesional hyperpigmentation and patient preference	—

Countries

Korea, Republic of

Contacts

Public ContactSooHyun Kwon

Ajou University Hospital

kwonsoohyun88@gmail.com+82-31-219-5580

Outcome results